Xinhua Silk Road: Tasly remains China#s 2019 National Tech Innovation Demonstration Enterprise

Food and Healthcare Press Releases Friday August 16, 2019 10:06
BEIJING--16 Aug--PRNewswire/InfoQuest

Tasly Holding Group, one of China's leading pharmaceuticals companies, has recently passed through the country's review of National Technology Innovation Demonstration Enterprise in 2019, thanks to its continuous innovations made in the recent years.

Tasly has developed the proprietary 5th-generation whole-process high speed dripping pill machine, which is regarded as a landmark equipment of modern intelligent production of traditional Chinese medicine (TCM).

The machine makes it possible to transform TCM from liquid to solid in a tube of over ten meters through electromagnetic levitation vibration and cryogenic technology, and turns the former bolus into small and micro dripping pill.

The machine with independent intellectual property rights not only represents a major breakthrough in the intelligent manufacturing of modern Chinese medicine, but also represents the direction of intelligent production of modern TCM.

Tasly is also determined to promote TCM in the global market, which means its products should stand the test of international standards.

"Our responsibility is to establish advanced standard and make every detail perfect to make our products withstand the test of international standards," said Sun Wei, the QA Manager of International Industrial Center.

On the basis of deeply study towards drug regulations of China, America and Europe, Sun Wei and her team carried out research and evaluation of hundreds of testing methods and finally established 12 kinds of quality control standard methods, which fully confirm that the quality of Compound Danshen Dripping Pill is stable and controllable.

Meanwhile, Tasly is committed to R&D of urgently needed drugs in clinical practice, and constructing a greater biomedical pattern featuring the coordinated development of modern TCM, chemical drugs and biological drugs, with innovative upgrades made in every element of the whole industrial chain.

See the original link: https://en.imsilkroad.com/p/307668.html
Video - https://cdn4.prnasia.com/002071/mnr/201908/tasly/video.mp4

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics